Draft:Nadav Ahituv

Source: Wikipedia, the free encyclopedia.

Nadav Ahituv is the Director for the Institute for Human Genetics at the University of California, San Francisco (USCF).[1][2][3] He is also a Professor in the Department of Bioengineering and Therapeutic Sciences and leads the Ahituv Lab at University of California, San Francisco (USCF).[1][4]

Early Life and Education

He received his PhD with distinction in human genetics from Tel-Aviv University, where he worked on hereditary hearing loss.[1][3][2]

Research

Ahituv pioneered cis-regulation therapy (CRT) for genetic diseases that are caused due to low gene dosage and adipose manipulation transplantation (AMT) that engineers fat cells and implants them for therapeutic benefits.[5][6]

The Ahituv Lab investigates gene regulatory elements and their relationship to human diversity and disease.[4] The lab also focuses on identifying gene regulatory elements and linking nucleotide variation within them to various phenotypes, including morphological differences between species, drug response, and human disease.[7] The lab is co-developed massively parallel reporter assays (MPRAs) that allow for high-throughput functional characterization of gene regulatory elements.[8]

Awards and Honors

In 2014, Ahituv received the prestigious ASCPT Leon I. Goldberg young investigator award from The American Society for Clinical Pharmacology and Therapeutics.[9][1]

References

  1. ^ a b c d "Nadav Ahituv | UCSF Profiles". profiles.ucsf.edu. Retrieved 2024-03-05.
  2. ^ a b "Nadav Ahituv". Simons Institute for the Theory of Computing. Retrieved 2024-03-05.
  3. ^ a b "Speaker Template". PMWC Precision Medicine World Conference. Retrieved 2024-03-05.
  4. ^ a b "About · Ahituv Lab". Ahituv Lab. Retrieved 2024-03-05.
  5. S2CID 256746336
    .
  6. .
  7. ^ "Nadav Ahituv, PhD". UCSF Institute for Human Genetics. Retrieved 2024-03-05.
  8. PMID 35315433
    .
  9. ^ "Nadav Ahituv, PhD | Department of Medicine". medicine.ucsf.edu. Retrieved 2024-03-05.